Stefania Paolucci

List of Publications by Year
in descending order

128 papers	4,374 citations	109321 35 h-index	118850 62 g-index
129 all docs	129 docs citations	129 times ranked	8872 citing authors

#	Article	IF	Citations
1	Myocardial localization of coronavirus in COVIDâ€19 cardiogenic shock. European Journal of Heart Failure, 2020, 22, 911-915.	7.1	783
2	Performance of VivaDiag COVIDâ€19 IgM/IgG Rapid Test is inadequate for diagnosis of COVIDâ€19 in acute patients referring to emergency room department. Journal of Medical Virology, 2020, 92, 1724-1727.	5.0	205
3	Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9848-9853.	7.1	191
4	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8, 695.	3.6	186
5	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clinical Microbiology and Infection, 2020, 26, 1094.e1-1094.e5.	6.0	121
6	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Eurosurveillance, 2020, 25, .	7.0	119
7	Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. Journal of Clinical Virology, 1999, 14, 57-66.	3.1	114
8	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 2019, 70, 379-387.	3.7	109
9	Toward the Discovery of Novel Antiâ€HIV Drugs. Secondâ€Generation Inhibitors of the Cellular ATPase DDX3 with Improved Antiâ€HIV Activity: Synthesis, Structureâ€“Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation. ChemMedChem, 2011, 6, 1371-1389.	3.2	95
10	Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: Need for mucosal viral load measurement. World Journal of Gastroenterology, 2015, 21, 1915.	3.3	91
11	Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: Towards the next generation HIV-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2094-2098.	2.2	85
12	Occurrence of Extended Spectrum Î²-Lactamases, KPC-Type, and MCR-1.2-Producing Enterobacteriaceae from Wells, River Water, and Wastewater Treatment Plants in OltrepÃ² Pavese Area, Northern Italy. Frontiers in Microbiology, 2017, 8, 2232.	3.5	85
13	Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naÃ¯ve patients. Virology Journal, 2013, 10, 355.	3.4	78
14	SARS Cov-2 infection in a renal-transplanted patient: A case report. American Journal of Transplantation, 2020, 20, 1882-1884.	4.7	76
15	Naturally occurring mutations to HCV protease inhibitors in treatment-naÃ¯ve patients. Virology Journal, 2012, 9, 245.	3.4	72
16	Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. Journal of Medical Virology, 2005, 75, 336-347.	5.0	70
17	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Journal of Hepatology, 2019, 71, 1106-1115.	3.7	69
18	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. International Journal of Infectious Diseases, 2021, 104, 315-319.	3.3	66

#	Article	IF	Citations
19	CXCR4 and CCR5 Genetic Polymorphisms in Long-Term Nonprogressive Human Immunodeficiency Virus Infection: Lack of Association with Mutations other than CCR5-Î”32. Journal of Virology, 1998, 72, 6215-6217.	3.4	58
20	Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. Journal of General Virology, 2012, 93, 889-899.	2.9	56
21	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy113.	0.9	56
22	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nature Communications, 2021, 12, 6032.	12.8	55
23	Changing circulation rate of human metapneumovirus strains and types among hospitalized pediatric patients during three consecutive winter-spring seasons. Archives of Virology, 2005, 150, 2365-2375.	2.1	54
24	Detection and pathogenicity of human metapneumovirus respiratory infection in pediatric Italian patients during a winterâ€“spring season. Journal of Clinical Virology, 2006, 35, 59-68.	3.1	53
25	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. Journal of Antimicrobial Chemotherapy, 2010, 65, 425-433.	3.0	53
26	The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA. Nucleic Acids Research, 2015, 43, 9405-9417.	14.5	51
27	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. Journal of Hospital Infection, 2020, 105, 474-476.	2.9	51
28	Kinetics of Epstein-Barr Virus DNA Load in Different Blood Compartments of Pediatric Recipients of T-Cell-Depleted HLA-Haploidentical Stem Cell Transplantation. Journal of Clinical Microbiology, 2008, 46, 3672-3677.	3.9	47
29	HIV-1-Specific T Cell Precursors with High Proliferative Capacity Correlate with Low Viremia and High CD4 Counts in Untreated Individuals. Journal of Immunology, 2008, 180, 5907-5915.	0.8	45
30	Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. Journal of Medical Virology, 2001, 65, 207-217.	5.0	44
31	Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. European Journal of Immunology, 1997, 27, 3166-3173.	2.9	43
32	Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. Archives of Virology, 2006, 151, 1225-1233.	2.1	43
33	Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4posT cells and macrophages. Retrovirology, 2013, 10, 154.	2.0	42
34	Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. Journal of Medical Virology, 2010, 82, 116-122.	5.0	41
35	Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. Journal of Clinical Microbiology, 1995, 33, 16-23.	3.9	41
36	Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. European Journal of Immunology, 1999, 29, 3629-3635.	2.9	38

#	Article	IF	Citations
37	Presence of hepatitis C virus (HCV) genomic RNA and viral replicative intermediates in bone marrow and peripheral blood mononuclear cells from HCV-infected patients. Vaccine Journal, 1994, 1, 160-163.	2.6	37
38	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1â€“4 in Italy. Scientific Reports, 2018, 8, 8988.	3.3	36
39	Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. Infectious Agents and Cancer, 2014, 9, 18.	2.6	34
40	Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virusâ€induced activation. Journal of Viral Hepatitis, 2015, 22, 391-398.	2.0	34
41	Processivity and drug-dependence of HIV-1 protease. Aids, 2003, 17, 663-671.	2.2	31
42	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. Journal of Hospital Infection, 2020, 105, 477-479.	2.9	31
43	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. Journal of Hepatology, 2018, 68, 597-600.	3.7	28
44	Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Scientific Reports, 2017, 7, 16017.	3.3	26
45	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	3.7	26
46	Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. Antiviral Research, 2000, 45, 101-114.	4.1	24
47	HIV-1 Subtype F1 Epidemiological Networks among Italian Heterosexual Males Are Associated with Introduction Events from South America. PLoS ONE, 2012, 7, e42223.	2.5	22
48	Nevirapine Resistance Mutation at Codon 181 of the HIV-1 Reverse Transcriptase Confers Stavudine Resistance by Increasing Nucleotide Substrate Discrimination and Phosphorolytic Activity. Journal of Biological Chemistry, 2003, 278, 15469-15472.	3.4	21
49	Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. Aids, 2003, 17, 1568-1570.	2.2	20
50	Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication. Antimicrobial Agents and Chemotherapy, 2004, 48, 4611-4617.	3.2	20
51	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. International Journal of Infectious Diseases, 2021, 109, 199-202.	3.3	20
52	Changes in circulation of B and non-B HIV strains: Spotlight on a reference centre for infectious diseases in Northern Italy. Journal of Medical Virology, 2008, 80, 947-952.	5.0	19
53	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiologica, 2012, 35, 17-25.	0.1	19
54	Hepatitis B virus preC mutants in human hepatocellular carcinoma tissues. Research in Virology, 1993, 144, 297-301.	0.7	17

#	Article	IF	Citations
55	Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. Journal of Viral Hepatitis, 1995, 2, 251-256.	2.0	17
56	The PDZ-Ligand and Src-Homology Type 3 Domains of Epidemic Avian Influenza Virus NS1 Protein Modulate Human Src Kinase Activity during Viral Infection. PLoS ONE, 2011, 6, e27789.	2.5	16
57	HIV integrase variability and genetic barrier in antiretroviral naÃ¯ve and experienced patients. Virology Journal, 2011, 8, 149.	3.4	16
58	Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. Journal of Clinical Virology, 2015, 72, 114-118.	3.1	15
59	Prevalence and determinants of resistance mutations in <scp>HIV</scp>â€1â€infected patients exposed to integrase inhibitors in a large Italian cohort. HIV Medicine, 2019, 20, 137-146.	2.2	15
60	Strategies to Decrease Viral Load Rebound, and Prevent Loss of Cd4 and Onset of Resistance during Structured Treatment Interruptions. Antiviral Therapy, 2004, 9, 123-132.	1.0	15
61	Emergence of Multiple Drugâ€Resistant Human Cytomegalovirus Variants in 2 Patients with Human Immunodeficiency Virus Infection Unresponsive to Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2002, 34, 1146-1149.	5.8	13
62	Screening and Management of HIV-2-Infected Individuals in Northern Italy. AIDS Patient Care and STDs, 2008, 22, 489-494.	2.5	13
63	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. Journal of Antimicrobial Chemotherapy, 2020, 75, 3349-3358.	3.0	13
64	Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy. Aids, 2003, 17, 924-927.	2.2	13
65	Adenoma-Carcinoma Sequence of Colorectum. Diagnostic Molecular Pathology, 1995, 4, 198-202.	2.1	12
66	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3â€infected patients within the Italian network VIRONETâ€C. Liver International, 2021, 41, 1802-1814.	3.9	12
67	A human hepatoma cell line (PLC/PRF/5) produces lung metastases and secretes HBsAg in nude mice. European Journal of Cancer & Clinical Oncology, 1982, 18, 381-389.	0.7	11
68	Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility. Antiviral Research, 2006, 69, 181-185.	4.1	11
69	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). Journal of Clinical Virology, 2018, 105, 112-117.	3.1	11
70	Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report. BMC Infectious Diseases, 2021, 21, 994.	2.9	11
71	Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2003, 51, 135-139.	3.0	10
72	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	4.9	10

#	Article	IF	Citations
73	Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. International Journal of Infectious Diseases, 2022, 122, 420-426.	3.3	10
74	Higher levels of HIV DNA in memory and naive CD4+ T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. Antiviral Research, 2001, 50, 197-206.	4.1	9
75	The Stereoselective Targeting of a Specific Enzyme-Substrate Complex Is the Molecular Mechanism for the Synergic Inhibition of HIV-1 Reverse Transcriptase by (R)-(âˆ')-PPO464. Journal of Biological Chemistry, 2001, 276, 44653-44662.	3.4	9
76	NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. Antiviral Research, 2007, 76, 99-103.	4.1	9
77	Quantification and identification of polyomavirus DNA in blood and urine of renal transplant recipients. Diagnostic Microbiology and Infectious Disease, 2007, 57, 301-307.	1.8	8
78	Genotypic Determination of HIV Tropism in a Cohort of Patients Perinatally Infected With HIV-1 and Exposed to Antiretroviral Therapy. HIV Clinical Trials, 2014, 15, 45-50.	2.0	8
79	HCV Intergenotype 2k/1b Recombinant Detected in a DAA-Treated Patient in Italy. Antiviral Therapy, 2017, 22, 365-368.	1.0	8
80	No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.. Antiviral Research, 2019, 172, 104635.	4.1	8
81	No evidence of SARS-CoV-2 circulation in the framework of influenza surveillance between October 2019 and February 2020 in Lombardy, Italy. Travel Medicine and Infectious Disease, 2021, 40, 102002.	3.0	8
82	Chronic liver disease and active hepatitis C virus infection in patients with antibodies to this virus.. Journal of Clinical Pathology, 1994, 47, 148-151.	2.0	7
83	Accumulation of Defective HIV-1 Variants in a Patient with Slow Disease Progression. Current HIV Research, 2011, 9, 17-22.	0.5	7
84	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection, 2014, 42, 61-71.	4.7	7
85	Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. Research in Virology, 1993, 144, 303-306.	0.7	6
86	Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemics. Virology Journal, 2010, 7, 209.	3.4	6
87	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007â€"2009. Clinical Microbiology and Infection, 2011, 17, 1352-1355.	6.0	6
88	Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV. Journal of Virological Methods, 2012, 184, 103-105.	2.1	6
89	Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants. Journal of Antimicrobial Chemotherapy, 2004, 53, 766-771.	3.0	5
90	Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. Clinical Microbiology and Infection, 2012, 18, E66-E70.	6.0	5

#	Article	IF	Citations
91	Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments. AIDS Research and Human Retroviruses, 2014, 30, 17-24.	1.1	5
92	Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clinical Microbiology and Infection, 2017, 23, 777.e1-777.e4.	6.0	5
93	Higher Short-Term Virologic Efficacy of Three-Class Versus Two-Class Highly Active Antiretroviral Salvage Therapy in HIV-Infected Patients. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 380-384.	2.9	4
94	HIV-1 Plasma Variants Encoding Truncated Reverse Transcriptase (RT) in a Patient With High RT-Specific CD8+ Memory T-Cell Response. Current HIV Research, 2009, 7, 302-310.	0.5	4
95	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. Journal of Clinical Virology, 2016, 78, 1-3.	3.1	4
96	Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations . Infection and Drug Resistance, 2019, Volume 12, 1975-1984.	2.7	4
97	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. Clinical Microbiology and Infection, 2020, 26, 1569-1571.	6.0	4
98	Detection of the SARSâ€CoVâ€2 in different biologic specimens from positive patients with COVIDâ€19, in Northern Italy. Pediatric Allergy and Immunology, 2020, 31, 72-74.	2.6	4
99	Assays for Determination of HIV Resistance to Antiviral Drugs. Current Drug Metabolism, 2004, 5, 317-319.	1.2	4
100	Outbreak of hepatitis C virus infections originating from a breach in safe injection practices before contrast-enhanced computed tomography scanning. Journal of Hospital Infection, 2020, 106, 600-604.	2.9	3
101	SARSâ€CoVâ€2 infections in pediatric patients: A comparison of three pandemic waves. Pediatric Allergy and Immunology, 2022, 33, 93-95.	2.6	3
102	Spread of multiple SARSâ€CoVâ€2 lineages Aprilâ€August 2020 anticipated the second pandemic wave in Lombardy (Italy). Pediatric Allergy and Immunology, 2022, 33, 89-92.	2.6	3
103	Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies. Journal of Hepatology, 2017, 66, S82-S83.	3.7	2
104	Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs. Viruses, 2020, 12, 255.	3.3	2
105	Phylogenetic Analysis of HIV Type 1 CRF02_AG in Multiple Genes in Italian and African Patients Living in Italy. AIDS Research and Human Retroviruses, 2014, 30, 812-818.	1.1	1
106	Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Digestive and Liver Disease, 2017, 49, e49-e50.	0.9	1
107	The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution. Journal of Hepatology, 2017, 66, S744-S745.	3.7	1
108	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. Journal of Viral Hepatitis, 2021, 28, 1443-1451.	2.0	1

#	Article	IF	Citations
109	Inhibitors of human immunodeficiency virus-1 replication targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase. Retrovirology, 2010, 7, .	2.0	0
110	Next generation of antiretroviral agents targeting the RNA binding site of the HIV-1 cellular cofactor DDX3: an innovative therapeutic approach. Retrovirology, 2012, 9, .	2.0	0
111	Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy. Digestive and Liver Disease, 2017, 49, e62-e63.	0.9	0
112	The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network. Digestive and Liver Disease, 2017, 49, e8.	0.9	0
113	Natural HCV resistance is common in Italy and differently associated to genotypes. Digestive and Liver Disease, 2017, 49, e52.	0.9	0
114	HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life. Digestive and Liver Disease, 2017, 49, e53.	0.9	0
115	Impact of cryoglobulinemia on HCV viral load measurements of different molecular diagnostic systems. Journal of Hepatology, 2017, 66, S705.	3.7	0
116	Characterization of resistance profiles in HCV 2-3-4 DAA-naÃ¯ve and DAA-experienced infected patients in Italy. Digestive and Liver Disease, 2018, 50, 46-47.	0.9	0
117	National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing. Digestive and Liver Disease, 2018, 50, 55-56.	0.9	0
118	12 weeks ombitasvir/paritaprevirâ€"ritonavirâ€¯+â€¯ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. Digestive and Liver Disease, 2018, 50, 703-706.	0.9	0
119	National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing. Journal of Hepatology, 2018, 68, S290-S291.	3.7	0
120	Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy. Journal of Hepatology, 2018, 68, S262-S263.	3.7	0
121	THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment. Journal of Hepatology, 2019, 70, e219-e220.	3.7	0
122	THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance. Journal of Hepatology, 2019, 70, e209-e210.	3.7	0
123	Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks. Digestive and Liver Disease, 2019, 51, e15.	0.9	0
124	Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. Digestive and Liver Disease, 2019, 51, e53-e54.	0.9	0
125	Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance. Digestive and Liver Disease, 2019, 51, e65-e66.	0.9	0
126	VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen. Digestive and Liver Disease, 2020, 52, e2-e3.	0.9	0

#	Article	IF	Citations
127	Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C. Digestive and Liver Disease, 2020, 52, e24-e25.	0.9	0
128	Emergence and takeover of pre-core mutants are associated to anti-HBE seroconversion and hepatitis remission in HBeAg chronic hepatitis B. Hepatology, 1993, 18, A114.	7.3	0